 |
|
|
| |
Hepatitis B Virus Surface Antigen Inhibition with GSK3228836 (ISIS 505358) in
Chronic Hepatitis B Patients on Stable Nucleos(t)ide Analogue Regimen and in
Nucleos(t)ide Analogue Naïve Patients:
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Man-Fung Yuen1, Jeong Heo2, Jeong-won Jang3, Jung-Hawn Yoon4, Young-Oh Kweon5, Sung-Jae Park6, C. Frank Bennett7, and T. Jesse Kwoh7
1Queen Mary Hospital, The University of Hong Kong, Hong Kong, 2Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea, 3Seoul St. Mary's Hospital, the Catholic University of Korea, Seoul, Republic of Korea, 4Seoul National University Hospital, Seoul, Republic of Korea, 5Kyungpook National University Hospital, Daegu, Republic of Korea, 6Inje University Busan Paik Hospital, Busan, Republic of Korea, 7Ionis Pharmaceuticals Inc., Carlsbad, CA USA
|
| |
|
|
|
|
|
